SCHEMBL24399571

SCHEMBL24399571

Cc1ccc2c(Nc3cc(S(C)(=O)=O)ccc3F)nccc2c1N

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TNNI3K Q59H18 2/20 0.43
RIPK2 O43353 2/20 0.40
RET P07949 1/20 0.40
KDR P35968 1/20 0.40
MAPK14 Q16539 1/20 0.40
PKMYT1 Q99640 1/20 0.40
ALDH3A1 P30838 1/20 0.39
CDK4 P11802 2/20 0.39
CDK2 P24941 2/20 0.39
P2RX7 Q99572 2/20 0.38
CCNE1 P24864 1/20 0.38
TGFBR1 P36897 7/20 0.38
MAP4K4 O95819 4/20 0.37
CSF1R P07333 2/20 0.36
RAF1 P04049 1/20 0.35
BRAF P15056 1/20 0.35
DDR1 Q08345 1/20 0.35
DDR2 Q16832 1/20 0.35
ROCK1 Q13464 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30559487 1.00 TNNI3K (0.43) TNNI3KRIPK2RETKDRMAPK14
SCHEMBL25373487 0.84 ALDH3A1 (0.47) TNNI3KRIPK2RETKDRMAPK14
SCHEMBL24399762 0.83 DHFR (0.40) TNNI3KKDRCDK2TGFBR1CSF1R
SCHEMBL24399614 0.82 ADORA2A (0.46) KDRCSF1RRAF1BRAFDDR1
SCHEMBL26210662 0.81 EGFR (0.45) TNNI3KRETKDRCSF1RRAF1
SCHEMBL29638638 0.81 EGFR (0.36) RETKDRCSF1RRAF1BRAF
SCHEMBL24399714 0.81 EGFR (0.36) RETKDRCSF1RRAF1BRAF
SCHEMBL26210446 0.80 EGFR (0.39) RIPK2RETKDRCDK2P2RX7
SCHEMBL30400458 0.79 BACE2 (0.39) RIPK2KDRCSF1RRAF1BRAF
SCHEMBL25374814 0.79 BACE2 (0.39) RIPK2KDRCSF1RRAF1BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) 2023-10-05 US disclosed
WO-2022089219-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF 四川科伦博泰生物医药股份有限公司 2022-05-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312556-A1 ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF AHR, ARNT, NOTUM TNNI3K 3537/4885RIPK2 4618/4885RET 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.